tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2015-3-24-33tumors-149Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSСовременное состояние проблемы лечения резистентного к радиоактивному йоду дифференицированного рака щитовидной железы и клинический случай длительного успешного лечения сорафенибомCurrent status of differetiated radioactive iodine-resistant thyroid cancer: case report of successful long-term treatment with sorafenibМУФАЗАЛОВФ. Ф.MUFAZALOVF. F.

д. м.н., профессор,заместитель главного врача

doctor of medical sciences, professor, RCOHC deputy chief physician, chief radiologist

prffm@mail.ruШАРИПОВАН. С.SHARIPOVAN. S.

врач-радиотерапевт

MD, radiologist

sh-nailya27@mail.ruГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан по радиологии, главный радиолог МЗ Республики БашкортостанРоссияGBUZ “Republican clinical oncological health center (RCOHC)” Bashkortostan Republic Ministry of HealthcareRussian Federationотделение радиологии № 2 ГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики БашкортостанРоссияDepartment of Radiology No. 2 in GBUZ “Republican clinical oncological health center (RCOHC)” Bashkortostan Republic Ministry of HealthcareRussian Federation201526102015032433Copyright © МУФАЗАЛОВ Ф.Ф., ШАРИПОВА Н.С., 20152015МУФАЗАЛОВ Ф.Ф., ШАРИПОВА Н.С.MUFAZALOV F.F., SHARIPOVA N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/149

Рак щитовидной железы (РЩЖ) является наиболее распространенным эндокринным злокачественным новообразованием. За последнее десятилетие заболеваемость РЩЖ в мире и в Российской Федерации (РФ) неуклонно растет [1, 2]. Так, в Соединенных Штатах Америки отмечается ежегодный прирост выявленных случаев РЩЖ на 6,4%, с частотой прироста смертности в среднем на 0,9% [3]. В РФ в период с 2003–2013 гг. численность контингента больных РЩЖ возрастает из года в год в среднем на 5,4%. В 2013 г. в РФ выявлено 9624 новых случаев РЩЖ, численность контингента больных на 100 000 населения составила 93,2 [1]. Дифференцированный рак щитовидной железы (ДРЩЖ) составляет более 90% всех типов РЩЖ [4].

Thyroid cancer is one of the most widespreaded malignant endocrine tumors. Morbidity is constantly increasing in the world and in Russian Federation during last decade [1, 2]. So, in the United States marked annual increase of diagnosed cases of thyroid cancer by 6.4% with increasing of mortality by 0.9% [3]. In Russian Federation marked annual increase of diagnosed cases by 5.4% in 2003–2013. In 2013 in Russian Federation diagnosed 9624 new cases of thyroid cancer with morbidity 93.2 on 100 000 citizens [1]. Differentiated thyroid cancer is more than 90% of all cases of thyroid cancer [4].

дифференцированный рак щитовидной железырезистентный к радиоактивному йодусорафенибленватинибradioactive iodine-resistant differentiated thyroid cancersorafeniblenvatinibReferencesА. Д. Каприн, В. В. Старинский, Г. В. Петрова. Состояние онкологической помощи населению России в 2012 году. М. –2013. Kaprin A. D., Starinskiy V. V., Petrova G. V. Current status of oncological healthcare in Russia in 2012. M. –2013.А. Д. Каприн, В. В. Старинский, Г. В. Петрова. Состояние онкологической помощи населению России в 2012 году. М. –2013. Kaprin A. D., Starinskiy V. V., Petrova G. V. Current status of oncological healthcare in Russia in 2012. M. –2013.Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. and Vigneri, R. (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212.Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. and Vigneri, R. (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212.National Cancer Institute Surveillance, Epidemiology, and End Results program (NCI SEER) stat fact sheet: http://seer.cancer.gov/statfacts/html/thyro.htmlNational Cancer Institute Surveillance, Epidemiology, and End Results program (NCI SEER) stat fact sheet: http://seer.cancer.gov/statfacts/html/thyro.htmlNCI SEER cancer statistics review: http://seer.cancer.gov/csr/1975_2010/results_merged/sect_26_thyroid.pdfNCI SEER cancer statistics review: http://seer.cancer.gov/csr/1975_2010/results_merged/sect_26_thyroid.pdfNCCN (2014) NCCN Clinical Practice Guidelines in Oncology. Cancer-related Fatigue (version 1.2014). Fort Washington, PA: National Comprehensive Cancer Network.NCCN (2014) NCCN Clinical Practice Guidelines in Oncology. Cancer-related Fatigue (version 1.2014). Fort Washington, PA: National Comprehensive Cancer Network.Cooper, D., Doherty, G., Haugen, B., Kloos, R. and Al., E. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–1214.Cooper, D., Doherty, G., Haugen, B., Kloos, R. and Al., E. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–1214.Hundahl, S., Fleming, I., Fremgen, A. and Menck, H. (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83: 2638–2648.Hundahl, S., Fleming, I., Fremgen, A. and Menck, H. (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83: 2638–2648.Sciuto, R., Romano, L., Rea, S., Marandino, F., Sperduti, I. and Maini, C. (2009) Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 20: 1728–1735.Sciuto, R., Romano, L., Rea, S., Marandino, F., Sperduti, I. and Maini, C. (2009) Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 20: 1728–1735.Pacini, F. and Castagna, M. (2012) Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am 96: 369–383.Pacini, F. and Castagna, M. (2012) Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am 96: 369–383.Xing, M., Haugen, B. and Schlumberger, M. (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381: 1058–1069.Xing, M., Haugen, B. and Schlumberger, M. (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381: 1058–1069.Amin, A., Badwey, A. and El-Fatah, S. (2014) Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin Nucl Med 39: 142–146.Amin, A., Badwey, A. and El-Fatah, S. (2014) Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin Nucl Med 39: 142–146.Nixon, I., Whitcher, M., Palmer, F., Tuttle, R., Shaha, A., Shah, J. et al. (2012) The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22: 884–889.Nixon, I., Whitcher, M., Palmer, F., Tuttle, R., Shaha, A., Shah, J. et al. (2012) The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22: 884–889.Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. et al. (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892–2899.Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. et al. (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892–2899.Robbins, R., Wan, Q., Grewal, R., Reibke, R., Gonen, M., Strauss, H. et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18f] fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91: 498–505.Robbins, R., Wan, Q., Grewal, R., Reibke, R., Gonen, M., Strauss, H. et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18f] fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91: 498–505.Shimaoka, K., Schoenfeld, D., Dewys, W., Creech, R. and Deconti, R. (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160.Shimaoka, K., Schoenfeld, D., Dewys, W., Creech, R. and Deconti, R. (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160.Matuszczyk, A., Petersenn, S., Bockisch, A., Gorges, R., Sheu, S., Veit, P. et al. (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40: 210–213.Matuszczyk, A., Petersenn, S., Bockisch, A., Gorges, R., Sheu, S., Veit, P. et al. (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40: 210–213.NCCN (2013) NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma (version 2.2013). Fort Washington, PA: National Comprehensive Cancer Network.NCCN (2013) NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma (version 2.2013). Fort Washington, PA: National Comprehensive Cancer Network.Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatmentof metastatic differentiated refractory thyroid carcinoma. Med Oncol 2012; 29:1421–8.Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatmentof metastatic differentiated refractory thyroid carcinoma. Med Oncol 2012; 29:1421–8.Sherman SI. Early clinical studies of novel therapies for thyroid can-cers. Endocrinol Metab Clin North Am 2008; 37:511–24, xi.Sherman SI. Early clinical studies of novel therapies for thyroid can-cers. Endocrinol Metab Clin North Am 2008; 37:511–24, xi.US Food and Drug Administration (2013) FDA news release: FDA approves nexavar to treat type of thyroid cancer. Silver Spring, MD.US Food and Drug Administration (2013) FDA news release: FDA approves nexavar to treat type of thyroid cancer. Silver Spring, MD.US Food and Drug Administration (2015) FDA news release: FDA approves Lenvima for a type of thyroid cancer.US Food and Drug Administration (2015) FDA news release: FDA approves Lenvima for a type of thyroid cancer.Wilhelm, S., Adnane, L., Newell, P., Villanueva, A., Llovet, J. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets bothRaf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129–3140.Wilhelm, S., Adnane, L., Newell, P., Villanueva, A., Llovet, J. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets bothRaf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129–3140.Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T. et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664–671.Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T. et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664–671.Okamoto, K., Kodama, K., Takase, K., Sugi, N., Yamamoto, Y., Iwata, M. et al. (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (e7080) against ret gene fusion-driven tumor models. Cancer Lett 340: 97–103.Okamoto, K., Kodama, K., Takase, K., Sugi, N., Yamamoto, Y., Iwata, M. et al. (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (e7080) against ret gene fusion-driven tumor models. Cancer Lett 340: 97–103.Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trialof sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714–9.Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trialof sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714–9.Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib inmetastatic thyroid cancer. J Clin Oncol 2009; 27:1675–84.Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib inmetastatic thyroid cancer. J Clin Oncol 2009; 27:1675–84.Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment withtyrosine kinase inhibitors for patients with differentiated thyroidcancer: the M D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588–95.Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment withtyrosine kinase inhibitors for patients with differentiated thyroidcancer: the M D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588–95.Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effectsof sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923–31.Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effectsof sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923–31.Marotta V, Ramundo V, Camera L, et al. Sorafenib in advancediodine-refractory differentiated thyroid cancer: efficacy, safety andexploratory analysis of role of serum thyroglobulin and FDG-PET.Clin Endocrinol (Oxf) 2012.Marotta V, Ramundo V, Camera L, et al. Sorafenib in advancediodine-refractory differentiated thyroid cancer: efficacy, safety andexploratory analysis of role of serum thyroglobulin and FDG-PET.Clin Endocrinol (Oxf) 2012.Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioac-tive iodine-refractory, locally advanced or metastatic differentiatedthyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014.Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioac-tive iodine-refractory, locally advanced or metastatic differentiatedthyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014.Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)- refractory, differentiated thyroid cancer. BMC Cancer. 2011; 11:349.Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)- refractory, differentiated thyroid cancer. BMC Cancer. 2011; 11:349.Schlumberger, M., Tahara, M., Wirth, L., Robinson, B., Brose, M., Elisei, R. et al. (2014) A phase 3, multicenter, randomized, double-blind, placebocontrolled trial of lenvatinib (E7080) in patients with131-I-refractory differentiated thyroid cancer (SELECT) [Abstract LBA6008]. Paper presented at American Society of Clinical Oncology, Chicago, IL, 30 May-3 June 2013.Schlumberger, M., Tahara, M., Wirth, L., Robinson, B., Brose, M., Elisei, R. et al. (2014) A phase 3, multicenter, randomized, double-blind, placebocontrolled trial of lenvatinib (E7080) in patients with131-I-refractory differentiated thyroid cancer (SELECT) [Abstract LBA6008]. Paper presented at American Society of Clinical Oncology, Chicago, IL, 30 May-3 June 2013.Eisai Inc. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I refractory differentiated thyroid cancer. http://clinicaltrials.gov/ct2/show/NCT01321554?term=lenvatinib+AND+thyroid+cancer&r. Accessed July 2, 2013.Eisai Inc. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I refractory differentiated thyroid cancer. http://clinicaltrials.gov/ct2/show/NCT01321554?term=lenvatinib+AND+thyroid+cancer&r. Accessed July 2, 2013.Sherman, E., Ho, A., Fury, M., Baxi, S., Haque, S., Lipson, B. et al. (2013) Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 31: 6024.Sherman, E., Ho, A., Fury, M., Baxi, S., Haque, S., Lipson, B. et al. (2013) Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 31: 6024.Sherman, E., Ho, A., Fury, M., Baxi, S., Haque, S., Korte, S. et al. (2012) A phase II study of temsirolimus/ sorafenib in patients with radioactive iodine (RAI)- refractory thyroid arcinoma. J Clin Oncol 30: 5514.Sherman, E., Ho, A., Fury, M., Baxi, S., Haque, S., Korte, S. et al. (2012) A phase II study of temsirolimus/ sorafenib in patients with radioactive iodine (RAI)- refractory thyroid arcinoma. J Clin Oncol 30: 5514.Ho, A., Grewal, R., Leboeuf, R., Sherman, E., Pfister, D., Deandreis, D. et al. (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368: 623–632.Ho, A., Grewal, R., Leboeuf, R., Sherman, E., Pfister, D., Deandreis, D. et al. (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368: 623–632.ClinicalTrials.gov identifier: NCT00970359.ClinicalTrials.gov identifier: NCT00970359.Sacks, W. and Braunstein, G. (2013) Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract: 1–36.Sacks, W. and Braunstein, G. (2013) Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract: 1–36.The resolution of the expert council for targeted therapy of radioiodine refractory differentiated thyroid cancer. ¦-§: ¨©ª«§¬ ®«§«¯° ¬ ±²¬ ³ 3, 2014, µ¶·.10–11.The resolution of the expert council for targeted therapy of radioiodine refractory differentiated thyroid cancer. ¦-§: ¨©ª«§¬ ®«§«¯° ¬ ±²¬ ³ 3, 2014, µ¶·.10–11.Worden F. Treatment strategies for radioactive iodinerefractorydifferentiated thyroid cancer/ Ther Adv Med Oncol 2014, Vol. 6(6) 267–279 DOI: 10.1177/ 1758834014548188.Worden F. Treatment strategies for radioactive iodinerefractorydifferentiated thyroid cancer/ Ther Adv Med Oncol 2014, Vol. 6(6) 267–279 DOI: 10.1177/ 1758834014548188.Schreinemakers, J., Vriens, M., Munoz-Perez, N., Guerrero, M., Suh, I., Rinkes, I. et al. (2012) Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol 10:192.Schreinemakers, J., Vriens, M., Munoz-Perez, N., Guerrero, M., Suh, I., Rinkes, I. et al. (2012) Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol 10:192.Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F. et al. (2014) Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 13:70215–70218.Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F. et al. (2014) Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 13:70215–70218.

The authors declare that there are no conflicts of interest present.